The effect of vitamin K2 supplementation on cardiovascular risk markers.
Phase 2
Completed
- Conditions
- arteriosclerosis10003216
- Registration Number
- NL-OMON35262
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
-Men and women aged >= 40 and <= 65 years at Day 01 of the study
-Postmenopausal assessed by self-reported absence of menstrual periods for at least 1 year
-Body mass index (BMI) >= 18.5 and <= 30
Exclusion Criteria
-Using vitamin K antagonists
-Using chronic medication for cardiovascular diseases (beta blockers, bloodthinner medication, rate control medication, cholesterol lowering medication, diuretics, vasodilators)
-For women: using menopausal hormone therapy
-having a known history with coagulation problems
-Smokers
-Using vitamin supplements that contain vitamin K, vitamin D or calcium
-A high vitamin K2 intake (>= 90 µg/day)
-Consuming natto
-Vegans
-Soy allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method